EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 29 / No 5 (Mai 2013) Med Sci (Paris), 29 5 (2013) 523-528 References
Free Access
Issue
Med Sci (Paris)
Volume 29, Number 5, Mai 2013
Page(s) 523 - 528
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2013295016
Published online 28 May 2013
  1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964 ; 86 : 1646–1647. [CrossRef] [Google Scholar]
  2. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharm 2010 ; 160 : 480–498. [CrossRef] [Google Scholar]
  3. Fogli S, Breschi MC. The molecular bases of cannabinoid action in cancer. Cancer Therapy 2008 ; 6 : 103–116. [Google Scholar]
  4. MacCoun R, Reuter P. Evaluating alternative cannabis regimes. Br J Psychiatry 2001 ; 178 : 123–128. [CrossRef] [PubMed] [Google Scholar]
  5. Hazekamp A, Grotenhermen F. Review on clinical studies with cannabis and cannabinoids 2005–2009. cannabinoids 2010 ; 5 : 1–21. [Google Scholar]
  6. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003 ; 4 : 873–884. [CrossRef] [PubMed] [Google Scholar]
  7. Giuffrida R, Beltramo M, Piomelli D. Mechanism of endocannabinoid inactivation: biochemistry and pharmacology. J Pharm Exp Ther 2001 ; 298 : 7–14. [Google Scholar]
  8. Steffens S, Mach M. Vers un usage thérapeutique de ligands sélectifs du récepteur cannabinoïde 2 dans l’athérosclérose. Med Sci (Paris) 2006 ; 1 : 7–9. [CrossRef] [EDP Sciences] [Google Scholar]
  9. Vandevoorde S, Lambert DM. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 2005 ; 18 : 2647–2668. [CrossRef] [Google Scholar]
  10. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev 2008 ; 7 : 438–455. [CrossRef] [Google Scholar]
  11. Munro LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 ; 346 : 561–564. [CrossRef] [PubMed] [Google Scholar]
  12. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993 ; 365 : 61–65. [CrossRef] [PubMed] [Google Scholar]
  13. Onaivi ES. An endocannabinoid hypothesis of drug reward and drug addiction. Ann N Y Acad Sci 2008 ; 1139 : 412–421. [CrossRef] [PubMed] [Google Scholar]
  14. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995 ; 232 : 54–61. [CrossRef] [PubMed] [Google Scholar]
  15. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005 ; 310 : 329–332. [CrossRef] [PubMed] [Google Scholar]
  16. Yang P, Wang L, Xie X-Q. Latest advances in novel cannabinoid CB2 ligands for drug abuse and their therapeutic potential. Future Med Chem 2012 ; 4 : 187–204. [CrossRef] [PubMed] [Google Scholar]
  17. Sharir H, Console-Bram L, Mundy C, et al. The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol 2012 ; 7 : 56–65. [CrossRef] [Google Scholar]
  18. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010 ; 17 : 1430–49. [CrossRef] [PubMed] [Google Scholar]
  19. Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 2003 ; 139 : 775–786. [CrossRef] [PubMed] [Google Scholar]
  20. Venance L, Maldonado R. Manzoni. Le système endocannabinoïde central. Med Sci Paris 2004 ; 1 : 45–53. [Google Scholar]
  21. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011 ; 50 : 193–211. [CrossRef] [PubMed] [Google Scholar]
  22. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005 ; 129 : 437–453. [PubMed] [Google Scholar]
  23. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002 ; 347 : 417–429. [CrossRef] [PubMed] [Google Scholar]
  24. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut 2006 ; 55 : 1373–1376. [CrossRef] [PubMed] [Google Scholar]
  25. Ihenetu K, Molleman A, Parsons ME, et al. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 2003 ; 458 : 207–215. [CrossRef] [PubMed] [Google Scholar]
  26. Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med 2004 ; 10 : 678–679. [CrossRef] [PubMed] [Google Scholar]
  27. Ehrhart J, Obregon D, Mori T, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflam 2005 ; 2 : 29. [CrossRef] [Google Scholar]
  28. Leleu-Chavain N, Body-Malapel M, Spencer J, et al. Recent advances in the development of selective CB2 agonists as promising anti-inflammatory agents. Curr Med Chem 2012 ; 19 : 3457–3474. [CrossRef] [PubMed] [Google Scholar]
  29. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 1998 ; 394 : 277–281. [CrossRef] [PubMed] [Google Scholar]
  30. Guindon J, Beaulieu P. Antihyperlagesic effects of local injections of anandamide, ibuprofenn rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 2006 ; 50 : 814–823. [CrossRef] [PubMed] [Google Scholar]
  31. Kikuchi A, Ohashi K, Sugie Y, et al. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 2008 ; 106 : 219–224. [CrossRef] [PubMed] [Google Scholar]
  32. Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. J Psychoactive Drugs 2012 ; 44 : 125–133. [CrossRef] [PubMed] [Google Scholar]
  33. Calvino B. Les kératinocytes : des cellules non neuronales impliquées dans la douleur. Douleurs Évaluation - Diagnostic - Traitement 2010 ; 11 : 120–130. [CrossRef] [Google Scholar]
  34. Sarfaraz S, Afaq F, Adhami VM, et al. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005 ; 65 : 1635–1641. [CrossRef] [PubMed] [Google Scholar]
  35. Blazquez C, Casanova ML, Planas A, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003 ; 17 : 529–531. [PubMed] [Google Scholar]
  36. Fatima Teixeira-Clerc, Boris Julien, Pascale Grenard, et al. Les antagonistes du récepteur CB1 des cannabinoïdes : une nouvelle approche pour le traitement de la fibrose hépatique. Med Sci (Paris) 2006 ; 22 : 683–685. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.